This article originally
The FDA has granted priority review to a new drug application (NDA) seeking the approval of sonrotoclax (BGB-11417; BeOne Medicines) for the treatment of adult patients with relapsed or refractory mantle…
Sonrotoclax Receives FDA Priority Review for R/R Mantle Cell Lymphoma
